After watching him at the helm of the rapidly sinking DoubleTwist during the last few years, industry observers might understandably have doubted that former president Rob Williamson would land another job in the field anytime soon. But as it happened, he was snapped up as president and COO of Eos Biotechnology through that company’s CEO, David Martin. The process was so quick, in fact, that Williamson found himself signing the official papers at the San Francisco airport before flying off with Martin to negotiate a deal for Eos.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.